Plenary Session - From Bench to Bedside and Back: the development and FDA approval of vemurafenib for melanoma patients

10/06/2026 17:30 18:15

Room P1+2+3

Time	Session

17:30 17:40	Learnings from RAF inhibitor drug discovery Gideon Bollag Speaker USA
17:40 17:50	Resistance to BRAF Inhibition: Consequences and Therapeutic Opportunities Darrin Stuart Speaker Switzerland
17:50 18:00	Learning the biology of BRAF mutant cancers from the determinants of therapeutic resistance KeithFlaherty Speaker USA
18:00 18:15	Discussion